RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer

Table 5

Relationship between G allele for rs5030789 in RAD51 and rs1799796 in XRCC3 and clinicopathological characteristics of prostate cancer patients.

Clinicopathological parameter	rs5030789		rs1799796
	A	G	A	G
Age
≤ 71	35	67	60	42
> 71	24	72	41	55
	OR = 1.567 (0.846-2.902)		OR = 1.916 (1.089-3.371)
	p = 0.202		p = 0.033
PSAT (ng/ml)
< 4-10	34	68	53	49
> 10	25	71	48	48
	OR = 1.420 (0.768-2.624)		OR = 1.082 (0.619-1.889)
	p = 0.335		p = 0.887
Free/total PSA (F/T PSA)
< 0.16	25	71	44	52
≥ 0.16	34	68	57	45
	OR = 0.704 (0.381-1.301)		OR = 0.668 (0.381-1.170)
	p = 0.335		p = 0.203
PSA Density (PSAD, ng/ml)
< 0.28	26	72	49	49
≥ 0.28	33	67	52	48
	OR = 0.733 (0.397-1.352)		OR = 0.923 (0.529-1.612)
	p = 0.399		p = 0.888
Prostate volume (ml)
< 48	31	61	52	40
≥ 48	28	78	49	57
	OR = 1.416 (0.768-2.608)		OR = 1.512 (0.862-2.652)
	p = 0.337		p = 0.192
Gleason score
< 7	19	37	37	19
≥ 7	40	102	64	78
	OR = 1.309 (0.675-2.541)		OR = 2.373 (1.246-4.521)
	p = 0.532		p = 0.012
Cancer stage
T1-T2	35	81	58	58
T3-T4	24	58	43	39
	OR = 1.224 (0.664-2.256)		OR = 0.907 (0.515-1.597)
	p = 0.624		p = 0.841